A5036947490- Tuberculosis Research and Epidemiology
- Pneumonia and Respiratory Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- Infectious Diseases and Tuberculosis
- Mycobacterium research and diagnosis
- Global Health and Surgery
- Health and Conflict Studies
- Healthcare Systems and Reforms
- HIV/AIDS Impact and Responses
- Global Public Health Policies and Epidemiology
- HIV/AIDS drug development and treatment
- Global Maternal and Child Health
- COVID-19 and Mental Health
- Vaccine Coverage and Hesitancy
- Viral Infections and Outbreaks Research
- Health Systems, Economic Evaluations, Quality of Life
- Diagnosis and treatment of tuberculosis
- COVID-19 Clinical Research Studies
- Pharmaceutical Economics and Policy
- COVID-19 epidemiological studies
- Human Rights and Development
- Data-Driven Disease Surveillance
- Global Health Workforce Issues
- Obesity and Health Practices
- Ethics in medical practice
Brigham and Women's Hospital
2015-2025
Harvard Global Health Institute
2015-2025
Harvard University
2015-2025
Partners In Health
2012-2023
Center for Global Health
2017-2023
Harvard University Press
2012-2022
EsSALUD
2022
Emory University
2021
Yale University
2021
Indus Hospital
2021
The American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America jointly sponsored the development this guideline treatment drug-susceptible tuberculosis, which is also endorsed by European Respiratory US National Tuberculosis Controllers Association. Representatives from Academy Pediatrics, Canadian International Union Against Lung Disease, World Health Organization participated in guideline. This provides recommendations on clinical public...
The production of guidelines for the management drug-resistant tuberculosis (TB) fits mandate World Health Organization (WHO) to support countries in reinforcement patient care. WHO commissioned external reviews summarise evidence on priority questions regarding case-finding, treatment regimens multidrug-resistant TB (MDR-TB), monitoring response MDR-TB treatment, and models A multidisciplinary expert panel used Grading Recommendations Assessment, Development Evaluation (GRADE) approach...
Mycobacterium tuberculosis has been a major cause of human disease for centuries. This article discusses the development active drug therapy and emergence dissemination drug-resistant strains. Failure to manage properly puts us all at risk.
The American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America jointly sponsored the development this guideline treatment drug-susceptible tuberculosis, which is also endorsed by European Respiratory US National Tuberculosis Controllers Association. Representatives from Academy Pediatrics, Canadian International Union Against Lung Disease, World Health Organization participated in guideline. This provides recommendations on clinical public...
The COVID-19 pandemic demonstrates the critical need to reimagine and repair broken systems of global health. Specifically, hollowness health rhetoric equity, weaknesses a security-driven agenda, negative impacts power differentials not only globally, but also regionally locally. This article analyses effects these inequities calls on governments, multilateral agencies, universities, NGOs engage in true collaboration partnership this historic moment. Before spreads further - including Global...
In response to the COVID-19 epidemic, China implemented a series of interventions that impacted tuberculosis (TB) control in country.Based on routine surveillance data and questionnaires, study analyzed TB notification, follow-up examinations, treatment outcomes. The were split into three phases relation outbreak, lockdown reopen when nationwide started 2020: (11 weeks prior), intensive during immediately after), regular (4 additional weeks). Data from 2017-2019 used as baseline.The notified...
Vaccination plus Decarceration With the rollout of Covid vaccines, public debate regarding health in jails and prisons has increasingly shifted from decarceration toward vaccination incarcerated...
In 2022, students at North American universities with third-dose COVID-19 vaccine mandates risk disenrolment if unvaccinated. To assess the appropriateness of booster in this age group, we combine empirical risk-benefit assessment and ethical analysis. prevent one hospitalisation over a 6-month period, estimate that 31 207–42 836 young adults aged 18–29 years must receive third mRNA vaccine. Booster are expected to cause net harm: per prevented, anticipate least 18.5 serious adverse events...